Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc.
作者信息
Traets Marissa J M, Fischer Kathelijn, Uitslager Nanda, van der Valk Paul R, Kremer Hovinga Idske C L, van Vulpen Lize F D, Schutgens Roger E G
机构信息
Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
出版信息
TH Open. 2020 Nov 8;4(4):e362-e364. doi: 10.1055/s-0040-1718416. eCollection 2020 Oct.
Abstract
摘要
相似文献
1
Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc.重组凝血因子VIII-融合蛋白（rFVIII-Fc）和重组凝血因子IX-融合蛋白（rFIX-Fc）的真实药代动力学
TH Open. 2020 Nov 8;4(4):e362-e364. doi: 10.1055/s-0040-1718416. eCollection 2020 Oct.
2
Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.多中心 rFVIII-Fc（efmoroctocog alfa）药代动力学评价：真实世界研究，并与非延长半衰期 FVIII 浓缩物比较。
Haemophilia. 2020 Mar;26(2):282-289. doi: 10.1111/hae.13946. Epub 2020 Feb 27.
3
Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium.在钙离子存在或不存在的情况下，IX 因子-Fc 融合蛋白、IX 因子和纯化的 Fc 片段的构象可比性。
J Pharm Sci. 2012 May;101(5):1688-700. doi: 10.1002/jps.23064. Epub 2012 Jan 23.
4
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.A型血友病和 B 型血友病患者中重组因子 VIII Fc 和重组因子 IX Fc 的临床应用。
Haemophilia. 2018 May;24(3):414-419. doi: 10.1111/hae.13432. Epub 2018 Feb 5.
5
Factor VIII Fc Fusion Protein but not FVIII Drives Human Monocyte-Derived Dendritic Cell Activation via FcγRIIa.凝血因子VIII Fc融合蛋白而非FVIII通过FcγRIIa驱动人单核细胞衍生树突状细胞活化。
Hemasphere. 2020 Jan 3;4(1):e330. doi: 10.1097/HS9.0000000000000330. eCollection 2020 Feb.
6
Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.重组因子IX Fc融合蛋白与传统重组因子IX产品的持续预防治疗：疗效及每周因子用量比较
J Med Econ. 2017 Apr;20(4):337-344. doi: 10.1080/13696998.2016.1265973. Epub 2016 Dec 21.
7
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.重组因子IX Fc融合蛋白维持完整的促凝血特性，并在血友病B小鼠中展现出延长的疗效。
PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.
8
Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?VIII 因子和重组 IX 因子的比较药代动力学：哪些凝血因子的半衰期应随年龄而变化？
Haemophilia. 2013 Nov;19(6):882-6. doi: 10.1111/hae.12253.
9
FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.FcRn从小鼠肝细胞中一条不依赖VWF的FVIII清除途径中拯救重组因子VIII Fc融合蛋白。
PLoS One. 2015 Apr 23;10(4):e0124930. doi: 10.1371/journal.pone.0124930. eCollection 2015.
10
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.意大利重组凝血因子VIII浓缩物治疗甲型血友病的现状：特点与临床益处
Front Med (Lausanne). 2019 Dec 3;6:261. doi: 10.3389/fmed.2019.00261. eCollection 2019.
引用本文的文献
1
Eftrenonacog Alfa: A Review in Haemophilia B.依非特仑那肽：用于乙型血友病的治疗。
Drugs. 2023 Jun;83(9):807-818. doi: 10.1007/s40265-023-01868-7. Epub 2023 Apr 21.
2
Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia.预测重度血友病患者转换为延长半衰期浓缩物后终末半衰期的个体变化
Hemasphere. 2022 Mar 21;6(4):e694. doi: 10.1097/HS9.0000000000000694. eCollection 2022 Apr.
本文引用的文献
1
Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.评估由标准半衰期（SHL）向延长半衰期（EHL）FVIII 预防性治疗转变对中重度 A 型血友病男孩健康相关生活质量（HRQoL）的影响：CHO-KLAT 工具得出的经验教训。
Haemophilia. 2020 Jan;26(1):73-78. doi: 10.1111/hae.13905. Epub 2019 Dec 22.
2
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.A型血友病和 B 型血友病患者中重组因子 VIII Fc 和重组因子 IX Fc 的临床应用。
Haemophilia. 2018 May;24(3):414-419. doi: 10.1111/hae.13432. Epub 2018 Feb 5.
3
Switching to extended half-life products in Canada - preliminary data.加拿大转向长效产品——初步数据。
Haemophilia. 2017 Jul;23(4):e365-e367. doi: 10.1111/hae.13245. Epub 2017 May 26.
4
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.重组因子IX Fc融合蛋白治疗儿童B型血友病（Kids B-LONG）：一项多中心、非随机3期研究的结果
Lancet Haematol. 2017 Feb;4(2):e75-e82. doi: 10.1016/S2352-3026(16)30193-4.
5
Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol.基于网络的血友病群体药代动力学服务（WAPPS-Hemo）的开发：研究方案。
JMIR Res Protoc. 2016 Dec 15;5(4):e239. doi: 10.2196/resprot.6558.
6
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.血友病 B 用重组凝血因子 IX Fc 融合蛋白的 3 期研究。
N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.
7
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.3 期研究重組凝血因子 VIII Fc 融合蛋白在重度 A 型血友病中的作用。
Blood. 2014 Jan 16;123(3):317-25. doi: 10.1182/blood-2013-10-529974. Epub 2013 Nov 13.
Zotero 插件